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Abstract
Background: Homeopathy is often sought by patients with depression. In classical homeopathy, the treatment
consists of two main elements: the case history and the prescription of an individually selected homeopathic
remedy. Previous data suggest that individualized homeopathic Q-potencies were not inferior to the antidepressant
fluoxetine in a sample of patients with moderate to severe depression. However, the question remains whether
individualized homeopathic Q-potencies and/or the type of the homeopathic case history have a specific
therapeutical effect in acute depression as this has not yet been investigated. The study aims to assess the two
components of individualized homeopathic treatment for acute depression, i.e., to investigate the specific effect of
individualized Q-potencies versus placebo and to investigate the effect of different approaches to the homeopathic
case history.
Methods/Design: A randomized, partially double-blind, placebo-controlled, four-armed trial using a 2 × 2 factorial
design with a six-week study duration per patient will be performed. 228 patients diagnosed with major
depression (moderate episode) by a psychiatrist will be included. The primary endpoint is the total score on the
17-item Hamilton Depression Rating Scale after six weeks. Secondary end points are: Hamilton Depression Rating
Scale total score after two and four weeks; response and remission rates, Beck Depression inventory total score,
quality of life and safety at two, four and six weeks. Statistical analyses will be by intention-to-treat. The main
endpoint will be analysed by a two-factorial analysis of covariance. Within this model generalized estimation
equations will be used to estimate differences between verum and placebo, and between both types of case
history.
Discussion: For the first time this study evaluates both the specific effect of homeopathic medicines and of a
homeopathic case taking in patients with depression. It is an attempt to deal with the challenges of homeopathic
research and the results might be useful information in the current discussion about the evidence on homeopathy
Trial registration: ClinicalTrials.gov: NCT01178255
Background
From 120 million people that suffer from depression
around the world, less than 25% receive adequate treat-
ment [1]. The estimated global burden of disease from
major depression, measured as “disability adjusted life
years” (DALY), is rising globally, making depression the
leading cause of DALYs in middle and high income
countries [2]. The overall prevalence of depressive disor-
ders in five European countries was 8.56%, with a higher
prevalence in urban Ireland (12.3%) and urban United
Kingdom (UK, 17.1%) [3]. The prevalence can be higher
in some age groups. For instance, in Berlin, Germany,
the prevalence of lifetime depression in 2008 was almost
20% for women between 18 and 29 years old, 25% for
women between 40 and 59 years old and, among men,
12% and 15% for the same age groups, respectively [4].
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work incapacity and for early retirement among women
[4]. This might be in spite of current treatments, which
do not seem to have any effect on reducing the number
of disabled persons per year [5].
According to the S3-Guidelines from the German
Society for Psychiatry, Psychotherapy and Neurology, an
antidepressant treatment is indicated to patients presenting
a moderate episode of major depression [6]. Although anti-
depressants are the standard pharmacotherapy for major
depression, with a significant difference to placebo, the
National Institute of Clinical Excellence (NICE) in the UK
stresses that the severity of depression at which antidepres-
sants show consistent benefits over placebo is poorly
defined, emphasizing that, in general, the more severe the
symptoms, the greater the benefit [7]. In moderate depres-
sion, for instance, there is evidence suggesting that there is
a statistically important difference favouring Serotonin
Selective Reuptake Inhibitors (SSRIs) over placebo on redu-
cing depression symptoms as measured by the Hamilton
Depression Rating Scale (HAM-D), but the size of this dif-
ference is unlikely to be of clinical importance (SMD =
-0.28; 95% CI, -0.48 to -0.08) [7] A recent patient-level
meta-analysis confirms these guidelines and previous data
[8], indicating small antidepressant benefits for patients
with mild (SMD -0.11; 95% CI -0.18 to 0.41) or moderate
depressive episodes (SMD -0.17; 95% CI-0.08 to 0.43 [9]).
Whereas, for patients with severe depression, the difference
was with a SMD of 0.47 (95% CI, 0.22 to 0.71), which is
very close to 0.50, i.e., a medium effect size [9].
The patient’s discontentment with antidepressants is a
reason cited for the search for other treatment options
[10]. In Ireland, for instance, individuals with a history
of depression were much more likely to seek comple-
mentary and alternative medicine (CAM) than those
who were not depressed [11]. Depression is also one of
the most commonly treated complaints at the outpatient
clinics of homeopathic hospitals in the UK National
Health Service [12].
Homeopathy is based on the ‘principle of similars’,
whereby substances that cause symptoms in healthy
individuals are used to stimulate healing in patients who
have similar symptoms when ill [13]. These substances
are usually administered in extremely high dilutions,
making homoeopathy a controversial and strongly
debated system. When a single homoeopathic remedy is
selected based on a patient’s total symptom picture, it is
called ‘classical’ homoeopathy [14].
In classical homeopathy (addressed in this protocol)
the treatment consists of two main elements: the case
history and the prescription of an individually selected
homeopathic remedy. The homeopathic case history
aims to ascertain the totality of signs and symptoms of
each patient, enabling the selection of an individualized
homeopathic medicine. In addition it attempts to under-
stand the patient’s background, environment and daily
routine. In some recent approaches the patient might fill
in a questionnaire prior to the medical consultation, to
improve the efficiency of obtaining the case history [15].
Homeopathic medicines are produced through
sequential agitated dilutions in Decimal (D), Centesimal
(C) or Quinquagintamillesimal (Q or LM) potencies. In
this study we will use Q-Potencies which are prepared
by grinding the raw material (C1 until C3), followed by
consecutive 1:50.000 agitated dilutions. Therefore a Q1
corresponds to a 5 × 10
-10 fraction of the raw material
( Q 2=2 . 5×1 0
-15, Q3 = 1.25 × 10
-20, Q4 = 6.25 × 10
-24,
etc.). To date, there is no clear evidence that homo-
pethic medicines are superior to placebo.
Results from a multi-center observational study with
3981 patients treated with classical homeopathy indicate
clinically relevant improvements in the mental aspects of
quality of life, after two and eight years of treatment obser-
vation [16]. However, it is not clear whether these results
can be attributed to the homeopathic treatment itself, or
are due to other factors or just placebo effects since the
study had no control group. However, according to a
recent trial from Brazil [17], classical homeopathy (i.e., the
“whole packet": a thorough case history + homeopathic
medicines) seems to be, at least, as effective as conven-
tional standard pharmacotherapy. Data from this rando-
mized, controlled, double-blind trial indicated that
individualized homeopathic Q-potencies were non-inferior
to the antidepressant fluoxetine in a sample of patients
with moderate to severe depression. Interestingly respon-
der rates (defined as a decrease of at least 50% from base-
line on the Montgomery & Åsberg depression rating scale)
of both the homeopathic medicine and fluoxetine groups
were higher (homeopathy 84.6%; fluoxetine 82.8%) than
those usually found for antidepressants in trials (43-75%)
[18]. One might speculate that this higher response rate
could be due to the more extensive homeopathic case his-
tory in the study that compared homeopathic medicines
with fluoxetine. However, neither the specific effect of
individualized homeopathic Q-potencies, nor the specific
effect of the homeopathic consultation has been investi-
gated for patients with depression.
Aims
The primary objective of this study is to assess the two
main components contributing to the individualized
homeopathic acute phase (6 weeks) treatment of depres-
sion (moderate episode), i.e., to investigate the specific
effect of individualized Q-potencies versus placebo and
to investigate the effect of different forms of taking a
homeopathic case history (case history type I and II).
Secondary objectives will be to investigate short term
effects (after two and four weeks), including differences
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as between the different techniques of homeopathic case
history, and to assess the effect of individualized Q-
potencies together with either form of case history. A
safety evaluation will also be performed.
Methods/Design
Study Design
A randomized, partially double-blind, placebo-con-
trolled, four-armed trial using a 2 × 2 factorial design
with a six week study duration per patient will be per-
formed to test two different hypotheses:
H0: homeopathic medicines = placebo (null hypoth-
esis) vs. H1: homeopathic medicines ≠ placebo (alter-
native hypothesis)
H0: homeopathic case history type I = case history type
II (null hypothesis) vs.H1: homeopathic case history
type I ≠ case history type II (alternative hypothesis)
To test these hypotheses, patients will be randomized
to one of four groups illustrated in Figure 1.
Participants
We will include male and female patients aged between
18 and 65 years diagnosed with moderately severe
(HAM-D 17 to 24) major depression by a psychiatrist,
patients must not be currently taking antidepressants or
anxiolytic drugs (with the exception of Lorazepam as
rescue medication, maximal dose 1.5 mg/day). Capability
and willingness to give informed consent and to comply
with the study procedures will also be required.
Exclusion criteria include current mild episode of
depression (HAM-D < 17), current severe episode of
depression (HAM-D > 24); schizophrenia or other psy-
chotic disorders, bipolar affective disorder, schizoaffec-
tive disorders, alcohol or other substance abuse, eating
disorders, a clinically significant (Diagnostic and Statisti-
cal Manual of Mental Disorders)-Axis II disorder; severe
depression, which previously motivated a suicide
attempt; a score of 4 or 5 in the Columbia-Suicide
Severity Rating Scale (C-SSRS) [19], up to three months
before screening; a clinically significant acute or chronic
disease that would hinder regular participation in the
study; treatment with antipsychotics, antidepressants,
sedatives/hypnotics or mood stabilizers four weeks prior
to the screening; complementary or alternative treat-
ment simultaneously to the study (for example, acu-
puncture, phytotherapy, etc.); homeopathic treatment
eight weeks prior to study entry; psychotherapy; simulta-
neous participation in another clinical trial (the last par-
ticipation in a previous clinical trial must be completed
at least three months prior to screening); concomitant
pregnancy or breastfeeding; patients who are assumed
to have a linguistic, intellectual or any other reason for
not understanding the meaning of the clinical trial and
for not complying with the necessary study procedures;
persons who have been institutionalized by a court
order; patients with an application for a pension.
Participants will be interviewed and treated by a medi-
cal doctor specialized in homeopathy at the CHAMP
outpatient clinic of Charité University Medical Center.
Interventions
Homeopathic case history - Type I or II
After inclusion, patients will be randomly assigned to
either case history type I or II, according to a randomi-
zation number disclosed from sequentially numbered,
Figure 1 Flow chart of the study groups.
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mation using different homeopathic techniques, in order
to assess their influence on depression severity. Type I
and II differ in the time used for the semi-standardized
questionnaire and the onsite patients-doctor interaction
and to ensure patients’ blinding are not further
described here. The content and structure of the ques-
tionnaire used in DEP-HOM follows Hahnemann’s case
history instructions [20], with some additional questions
stressing the symptoms of a depressive episode. The
questionnaire was developed in consensus with mem-
bers of the German Homeopathic Doctors Association
and pretested.
Individualized homeopathic Q-potencies or placebo
The selection of the individualized remedy (case analy-
sis) will be carried out after the case history, in the
absence of the patient, by medical doctor specialized in
homeopathy with 20 years experience classical homeop-
athy based on the the clinical-pharmaceutical protocol
[21] developed by Hahnemann, which includes the stan-
dardized use of ascending Q-potencies [20]. The investi-
gator is also experienced in case history and analysis
under double blind conditions [17].
Q-potencies will be provided from the study pharmacy
by Dr. Zinsser Arzneimittel, (Freudenstadt, Germany)
and are manufactured according to the methodology
described in the 6
th edition of the Organon. The prescrip-
tion of the individualized homeopathic Q-potency will be
sent to the Charité pharmacy, together with the patient’s
randomization number. According to the randomization
number, the study pharmacist will dissolve one sucrose
globule of the prescribed Q-potency (Q2) or one sucrose
globule (placebo) in 10 ml of 20% alcohol-distilled water
solvent. The vial will then be labeled and sent to the
study center, responsible for dispatching it to the patient
within three days from the first case history.
The standard dose will be one drop of the received vial
three times per week [21]. Follow-ups will be at two, four
and six weeks after the first clinical interview. Blinded
medicine, dosage or potency changes will be allowed on a
clinical basis. Basal Q-potency medicines stored by the
study Pharmacy are listed below (Appendix 1).
Outcomes
The primary endpoint is the mean total depression
score using the 17-item version of the Hamilton Dep-
ression Rating Scale (HAM-D) [22], after six weeks.
Severity of symptoms will be assessed by a blinded
investigator (psychologist) from the Clinic for Psychiatry
and Psychotherapy, Charité University Medical Center.
The secondary end points are the mean HAM-D total
scores after two and four weeks, response (decrease of
50% or more from baseline HAM-D score) and remis-
sion (HAM-D scores ≤ 7) rates, Beck Depression
inventory (BDI) [23] total score and mean SF-12 Health
Survey (SF-12) at weeks two, four and six.
Adverse events will be collected during the study and
will form part of the secondary endpoint data in deter-
mining the safety of homeopathic medicines. Serious
adverse effects from homeopathic medicine were not
observed on the non-inferiority trial [17] and are not
expected during the current study. Participants’ treat-
ment expectations at baseline will also be assessed.
Randomization and blinding
A non-stratified block randomization with variable block
lengths will be carried out, with a 2:1:1:2 ratio (aiming at
exposing a smaller number of participants to placebo
treatment) for group 1: group 2: group 3: group 4 (i.e.
76:38:38:76 patients). The randomization list was gener-
ated with SAS/BASE Software (SAS Inc., Cary NC,
USA), by a statistician not further involved in the study.
The patients will be assigned in sequential order to the
treatment groups.
The patients, the psychiatrist and the statistician will
remain blinded from the identity of the four treatment
groups until the end of the study. The study clinical
investigator will be unmasked for the case history type I
or II. The randomization list will be kept strictly confi-
dential. Only the study pharmacist and the statistician
who generated the randomization list have access to the
randomization list. During the study, unblinding will
only occur in the case of a patient emergency using
sealed emergency envelopes.
Data management
Data management services will be performed by the
study center at the Institute for Social Medicine, Epide-
miology and Health Economics - Charité University in
accordance with the ICH-Guidelines for Good Clinical
Practice and DIN EN ISO 2001.
Statistical Analysis
The following primary comparisons will be conducted
between the following groups: The specific effect of
homeopathic medicines compared to placebo (double
blind comparison), where essentially the groups 1+3 will
be compared to the groups 2+4. The effect of the
homeopathic case history (single-blind comparison),
where essentially groups 1+2( c a s eh i s t o r yt y p eI )a r e
compared to the groups 3+4 (case history type II).
Analysis for the primary endpoint
Statistical analysis will be by intention-to-treat, including
all patients randomized, regardless whether or not they
adhered to the treatment protocol or provided complete
data sets. Only patients who withdraw their consent to
use their personal data can be excluded from the
analysis.
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leads to prognostically balanced treatment groups, all
baseline parameters will be compared by two sided Chi-
square-tests (if nominally scaled) or Kruskal-Wallis-tests
(if ordinally or continuously scaled). The respective
p-values are descriptive in nature, not confirmative.
The primary endpoint will be analysed by a two-fac-
torial analysis of covariance (ANCOVA), modeling time
(3 levels: weeks 2, 4 and 6) as a within-group-factor,
type of case history (2 levels: types I and II), type of
medicine (2 levels: verum and placebo), and their
respective interaction as between-group factors, and
baseline value and patient’s expectation as linear covari-
ates. Within this model generalized estimation equations
(GEE) [24] will be used to estimate the 6-week differ-
ences between verum and placebo, and between both
types of case history. Two-sided p-values and confidence
intervals for both hypotheses will be adjusted by the
Bonferoni-Holm procedure [25]. As no interim analyses
are planned there is no need for further multiple adjust-
ments. The multiple level of significance is set at a =
0.05 (two-sided).
Sample size calculation
For this study we assumed that the verum treatment is
better than placebo by 2.7 ± 6.0 (mean ± standard devia-
tion) HAM-D score points after 6 weeks (corresponding
to a SMD = 0.45), that type II case history is better than
type I by 2.7 ± 6.0 score points (SMD = 0.45), and that
both effects do not interact. If so, a Bonferoni-adjusted F-
Test (multiple significance level a = 0.05, two-sided) has
a power of 83.5% to detect the difference between verum
and placebo and a power of 85.0% to detect the differ-
ence in case history taking, if 68 patients are included in
groups 1 and 3, and 34 patients are included in groups 2
and 4. This leads to a total number of 228 patients, if one
allows for a 10%drop-out rate per group.
Regulatory and Ethical approval
Regulatory approval
Bundesinstitut für Arzneimittel und Medizinprodukte
(BfArM), EudraCT Nr: 2009-017458-11, Submission-Nr.:
4036175.
Ethical approval
Ethics Committee, Berlin, Landesamt für Gesundheit
und Soziales (LaGeSo): ZS EK 15 099/10. This study is
in compliance in with the Helsinki Declaration and with
the International Conference on Harmonisation (ICH) -
Good Clinical Practice.
Discussion
For the first time this study evaluates both the specific
effect of homeopathic medicines and of a homeopathic
case taking in patients with depression. The protocol is
in accordance with the EMEA (European Medicines
Agency) Guidelines, which recommends placebo-con-
trolled studies and the duration of six weeks for trials
investigating medicines for depression [26], considering
that during antidepressant pharmacotherapy, one must
reckon with a delay of several weeks until sufficient
antidepressant effects can be seen [27].
It is the first trial on classical homeopathy after the
15
th amendment to the German Medicines Act (Arznei-
mittelgesetz, AMG) [28]. The study includes all relevant
aspects of the CONSORT guidelines for reporting ran-
domized homeopathic trials with parallel groups [29,30].
For ethical reasons, individuals with a previous suicide
attempt or a C-SSRS score of 4 or 5 will be excluded
and the occurrence of suicide ideation (with the same
C-SSRS severity) will determine the premature termina-
tion of the patient’s participation in the study. Depres-
sion severity will be limited to a maximum HAM-D
score of 24, because for more severe depression a treat-
ment with antidepressant is recommended [9].
The need of individual prescriptions in classical
homeopathy has been considered as ‘a severe obstacle
for any double-blind trial’ [31]. In fact, the selection of a
suitable, individualized homeopathic medicine will not
be always accomplished during the six weeks of acute
treatment, especially under double-blind conditions.
However, from an ethical point of view a longer placebo
treatment period is problematic.
This study is an experimental study with a focus on
efficacy and not a pragmatic trial with a focus on effec-
tiveness. It is an attempt to deal with the challenges of
homeopathic research [32] and the results might be use-
ful information in the current discussion about the evi-
dence on homeopathy.
Appendix 1
Q-potencies that will be stored at the Charité Pharmacy
(Q2 and Q3). Medicines not listed can optionally be
ordered and prescribed, as needed.
Agaricus muscarius, Alumina, Ammonium carboni-
cum, Ammonium muriaticum, Anacardium orientale,
Antimonium crudum, Arsenicum album, Aurum folia-
tum, Baryta carbonica, Borax, Calcarea aceticum,
Calcarea carbonica, Carbo animalis, Carbo vegetabilis,
Causticum, Cocculus indica, Colocynthis, Conium
maculatum, Digitalis, Graphites, Hepar sulphuris cal-
careum, Ignatia amara, Iodium, Kalium carbonicum,
Kalium nitricum, Lycopodium clavatum, Magnesia car-
bonica, Magnesia muriatica, Manganum, Mercurius
solubilis, Mezereum, Muriaticum acidum, Natrum car-
bonicum, Natrum muriaticum, Nitri acidum, Nux
v o m i c a ,P e t r o l e u m ,P h o s p h o ricum acidum, Phosphorus,
Platina, Pulsatilla pratensis, Rhus toxicodendron, Sepia
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Page 5 of 7succus, Silicea terra, Spigelia, Stanum, Staphisagria,
Sulphur, Sulphuricum acidum, Zincum.
Abbreviations
AMG: Arzneimittelgesetz; ANCOVA: analysis of covariance; BDI: Beck
Depression Inventar; BfArM: Bundesinstitut für Arzneimittel und
Medizinprodukte; CAM: complementary and alternative medicine; C-SSRS:
Columbia Suicide Severity Rating Scale; DALY: disability adjusted life years;
EMEA: European Medicines Agency; GEE: Generalized Estimated Equation;
HAM-D: Hamilton-Depressions-Skala; ICH: International Conference on
Harmonisation; LAGeSo: Landesamt für Gesundheit und Soziales; NICE:
National Institute of Clinical Excellence; Q-Potenzen:
QuinquagintamillesimalPotencies; SMD: Standardized Mean Difference; SF 12:
Short Form 12; SSRIs: Serotonin Selective Reuptake Inhibitors.
Acknowledgements
Albert Schmierer and Pharmacy Dr. Zinsser, Freudenstadt, Germany, for
providing the Q-Potencies.
Author details
1Institute for Social Medicine, Epidemiology and Health Economics; Charité
University Medical Center; D-10098 Berlin, Germany.
2Clinic for Psychiatry
and Psychotherapy, Charité University Medical Center; D-10098, Berlin,
Germany.
3Karl and Veronica Carstens-Foundation; Am Deimelsberg 36; D-
45276 Essen; Germany.
4Institute of General Practice, Technische Universität
München, Wolfgangstr. 8, D-81667, Munich, Germany.
Authors’ contributions
CMW, KL, SNW, MT and UCA participated in the design of the study. CMW,
SK, KL and UCA reviewed and discussed current data on antidepressants for
moderate depression and the ethical basis for a placebo controlled study on
homeopathy for depression. CMW, IB, FM, LS and UCA elaborated all study
documents, including those necessary for regulatory and ethical approval. RL
performed the statistical planning. CMW, KL, MT, RL, SK and UCA helped to
draft the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 September 2010 Accepted: 14 February 2011
Published: 14 February 2011
References
1. World Health Organization (WHO): 10 facts on the global burden of
disease, 2008. [http://www.who.int/features/factfiles/global_burden/facts/
en/index6.html].
2. World Health Organization (WHO): The global burden of disease, 2004
update. 2008 [http://www.who.int/healthinfo/global_burden_disease/
GBD_report_2004update_full.pdf].
3. Ayuso-Mateos JL, Vázquez-Barquero JL, Dowrick C, Lehtinen V, Dalgard OS,
Casey P, Wilkinson C, Lasa L, Page H, Dunn G, Wilkinson G, ODIN Group:
Depressive disorders in Europe: prevalence figures from the ODIN study.
Br J Psychiatry 2001, 179:308-16.
4. Meinlschmidt G: Basisbericht 2009. Gesundheitsberichterstattung Berlin.
Daten des Gesundheits- und Sozialwesens Senatsverwaltung für Gesundheit,
Umwelt und Verbraucherschutz., Berlin, Herausgeber.
5. Wedegärtner F, Sittaro NA, Emrich HM, Dietrich DE: Invalidisierung durch
affektive Erkrankungen - Lehren aus den Daten der
Gesundheitsberichterstattung des Bundes. Psychiatr Prax 2007, 34:
S252-S255.
6. Deutschen Gesellschaft für Psychiatrie, Psychotherapie und
Nervenheilkunde: S3-Leitlinie/NVL Unipolare Depression, 2009. [http://
www.depression.versorgungsleitlinien.de/].
7. National Institute for Health and Clinical Excellence: Depression: the
treatment and management of depression in adults (update). 2009
[http://www.nice.org.uk/CG90], (Clinical guideline 90.).
8. Khan A, Leventhal RM, Khan SR, Brown WA: Severity of depression and
response to antidepressants and placebo: an analysis of the Food and
Drug Administration database. J Clin Psychopharmacol 2002, 22(1):40-45.
9. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD,
Shelton RC, Fawcett J: Antidepressant Drug Effects and Depression
Severity: A Patient-Level Meta-analysis. JAMA 2010, 303(1):47-53.
10. Wu P, Fuller C, Liu X, Lee HC, Fan B, Hoven CW, Mandell D, Wade C,
Kronenberg F: Use of complementary and alternative medicine among
women with depression: results of a national survey. Psychiatr Serv 2007,
58(3):349-356.
11. Fox P, Coughlan B, Butler M, Kelleher C: Complementary alternative
medicine (CAM) use in Ireland: a secondary analysis of SLAN data.
Complement Ther Med 2010, 18(2):95-103.
12. Thompson EA, Mathie RT, Baitson ES, Barron SJ, Berkovitz SR, Brands M,
Fisher P, Kirby TM, Leckridge RW, Mercer SW, Nielsen HJ, Ratsey DH,
Reilly D, Roniger H, Whitmarsh TE: Towards standard setting for patient-
reported outcomes in the NHS homeopathic hospitals. Homeopathy 2008,
97(3):114-121.
13. Jonas W, Jacobs J: Healing with Homeopathy. New York, Warner; 1996.
14. Linde K, Clausius N, Ramirez G, Melchart D, Eitel F, Hedges LV, Jonas WB:
Are the clinical effects of homeopathy placebo effects? A meta-analysis
of placebo-controlled trials. Lancet 1997, 350:834-843.
15. Frei H: Polarity analysis, a new approach to increase the precision of
homeopathic prescriptions. Homeopathy 2009, 98(1):49-55.
16. Witt CM, Lüdtke R, Baur R, Willich SN: Homeopathic medical practice:
long-term results of a cohort with 3981 patientes. BMC Publich Health
2005, 5:115.
17. Adler UC, Paiva NMP, Cesar AT, Adler MS, Molina A, Padula AE, Calil HM:
Homeopathic individualized Q-potencies versus fluoxetine for moderate
to severe depression: double-blind, randomized non-inferiority trial. Evid
Based Complement Altern Med 2009 [http://ecam.oxfordjournals.org/cgi/
content/full/nep114], Advance Access published on August 17,.
18. Girardi P, Pompili M, Innamorati M, Mancini M, Serafini G, Mazzarini L, Del
Casale A, Tatarelli R, Baldessarini RJ: Duloxetine in acute major depression:
review of comparisons to placebo and standard antidepressants using
dissimilar methods. Hum Psychopharmacol 2009, 3:177-190.
19. Posner K, Brent C, Lucas C, Gould M, Stanley B, Brown G, Fisher P, Zelazny J,
Burke A, Oquendo M, Mann J: Columbia-Beurteilungsskala zur
Suizidalität., C-SSRS.
20. Hahnemann CFS: Organon der Heilkunst: aude sapere. 6. Aufl., hrsg. u.
mit Vorw. vers. von Richard Haehl, Leipzig, Schwuabe, 1921. Heidelberg,
Haug; 1988, § 246, 248, 270.
21. Adler UC, Cesar AT, Adler MS, Padula AE, Garozzo EN, Galhardi WP: From
pharmaceutical standardizing to clinical research: 20 years of experience
with fifty-millesimal potencies. Int J High Dilution Res 2009, 8(29):173-182
[http://www.feg.unesp.br/~ojs/index.php/ijhdr/article/view/367/408].
22. Collegium Internationale Psychiatriae Scalarum (Hrsg.): Internationale
Skalen für Psychiatrie. 2005, Weyer, F (redakt.Bearb.) Beltz Test - 5. Auflage.
23. Hautzinger M, Bailer M, Worall H, Keller F: Das Beck-Depressions-Inventar:
BDI. Bern: Huber Verlag; 1994.
24. Zeger SL, Liang KY, Albert PS: Models for Longitudinal Data: A
Generalized Estimating Equation Approach. Biometrics 1988,
44(4):1049-1060.
25. Holm S: A simple sequentially rejective Bonferroni test procedure.
Scand J Stat 1979, 6:65-70.
26. EMEA: Note for guidance on clinical investigation of medical products in
the treatment of depression.[http://www.ema.europa.eu/pdfs/human/ewp/
051897en.pdf].
27. Sartorius N, Baghai TC, Baldwin DS, Barrett B, Brand U, Fleischhacker W,
Goodwin G, Grunze H, Knapp M, Leonard BE, Lieberman J, Nakane Y,
Pinder RM, Schatzberg AF, Svestka J, Baumann P, Ghalib K, Markowitz JC,
Padberg F, Fink M, Furukawa T, Fountoulakis KN, Jensen P, Kanba S,
Riecher-Rössler A: Antidepressant medications and other treatments of
depressive disorders: a CINP Task Force report based on a review of
evidence. Int J Neuropsychopharmacol 2007, 10(Suppl 1):S1-207.
28. AMG 15: Novelle zur Änderung des AMG. 2009, vom 23.07.
29. Schulz KF, Altman DG, Moher D, CONSORT Group: CONSORT 2010
statement: updated guidelines for reporting parallel group randomised
trials. PLoS Med 2010, 24(3):e1000251, 7.
30. Dean ME, Coulter MK, Fisher P, Jobst KA, Walach H: Reporting data on
homeopathic treatments (RedHot): a supplement to CONSORT. J Altern
Complement Med 2007, 13(1):19-23.
31. Frei H, Everts R, von Ammon K, Kaufmann F, Walther D, Hsu-Schmitz SF,
Collenberg M, Fuhrer K, Hassink R, Steinlin M, Thurneysen A: Homeopathic
Adler et al. Trials 2011, 12:43
http://www.trialsjournal.com/content/12/1/43
Page 6 of 7treatment of children with attention deficit hyperactivity disorder: a
randomized, double blind, placebo controlled crossover trial.
Eur J Pediatr 2005 164:758-67.
32. Bell I: Depression research in homeopathy: Hopeless or hopeful?
Homeopathy 2005, 94:141-144.
doi:10.1186/1745-6215-12-43
Cite this article as: Adler et al.: Homeopathy for Depression - DEP-HOM:
study protocol for a randomized, partially double-blind, placebo
controlled, four armed study. Trials 2011 12:43.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Adler et al. Trials 2011, 12:43
http://www.trialsjournal.com/content/12/1/43
Page 7 of 7